PARP inhibitors in ovarian cancer: Mechanisms, resistance, and the promise of combination therapy

被引：6

作者：

Bhatia, Tejas ^{[1
]}

Doshi, Gaurav ^{[1
]}

Godad, Angel ^{[1
]}

机构：

[1] SVKMs Dr Bhanuben Nanavati Coll Pharm, Dept Pharmacol, VLM Rd,Mithibai Campus,,Vile Parle West, Mumbai 400056, Maharashtra, India

来源：

PATHOLOGY RESEARCH AND PRACTICE | 2024年 / 263卷

关键词：

Cancer; Poly ADP-ribose polymerase; PARP inhibitors; Ovarian cancer; Mutations; MUTATIONS; REPAIR;

D O I：

10.1016/j.prp.2024.155617

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Current approaches to treating ovarian cancer focus mainly on surgical cytoreduction and chemotherapy using platinum-based drugs, while newer methods such as immunotherapy are being investigated to enhance treatment outcomes. Treating ovarian cancer is complicated by challenges such as late-stage detection, tumor diversity, and limited treatment choices. Therefore, innovative strategies such as precision medicine and targeted therapies like PARPi (Poly ADP-Ribose Polymerase inhibitors) are increasingly necessary. The article highlights the significance of an innovative therapeutic approach focusing on PARPi in revolutionizing ovarian cancer treatment and improving patient outcomes. It covers the basic knowledge of PARP, its structure, and its function in DNA repair. It further emphasizes how inhibiting PARP can help in treating ovarian cancer. It elaborates on the mechanism of action of PARPi. It covers the clinical trials governing PARPi and the combination of drugs used with PARPi. It mentions how the resistance is developed to PARPi and the strategies to overcome the resistance developed.

引用

页数：12

共 112 条

[1]

A, Phase I/II Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination With Olaparib (PARP Inhibitor) in Patients With Advanced Solid Tumors

[2]

A, Phase 1B/2 Multicohort Umbrella Study to Evaluate the Safety and Efficacy of Novel Treatments And/Or Combinations of Treatments in Participants With Ovarian Cancer (OPAL)

[3]

A. Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Niraparib Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

[4] Description of a Retrospective Cohort of Epithelial Ovarian Cancer Patients with Brain Metastases: Evaluation of the Role of PARP Inhibitors in this Setting [J].

Alizzi, Zena ;

Roxburgh, Patricia ;

Cartwright, Douglas ;

McLaren, Alistair ;

Park, Sarah ;

Jones, Rachel ;

Greening, Semini ;

Hudson, Emma ;

Green, Clare ;

Gray, Simon ;

Khalique, Saira ;

Karteris, Emmanouil ;

Hall, Marcia .

JOURNAL OF CLINICAL MEDICINE, 2023, 12 (07)

[5] Ocoxin Oral Solution Triggers DNA Damage and Cell Death in Ovarian Cancer [J].

Almaraz-Postigo, Sheila ;

Sanz, Eduardo ;

Pandiella, Atanasio ;

Diaz-Rodriguez, Elena .

NUTRIENTS, 2024, 16 (15)

[6] PARP-2, a novel mammalian DNA damage-dependent poly(ADP-ribose) polymerase [J].

Amé, JC ;

Rolli, V ;

Schreiber, V ;

Niedergang, C ;

Apiou, F ;

Decker, P ;

Muller, S ;

Hoger, T ;

Murcia, JMD ;

de Murcia, G .

JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (25) :17860-17868

[7] The PARP superfamily [J].

Amé, JC ;

Spenlehauer, C ;

de Murcia, G .

BIOESSAYS, 2004, 26 (08) :882-893

[8]

American Cancer Society, 2024, Cancer Facts & Fig

[9]

[Anonymous], 2023, Health Oncol. Hematol.., DOI [10.36000/HBT.OH.2023.17.120, DOI 10.36000/HBT.OH.2023.17.120]

[10]

[Anonymous], A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer

← 1 2 3 4 5 6 7 8 9 10 →